Pharma companies set to supply ARVs for ‘treatment’
Though there is no formal cure discovered to treat the virus, the treatment protocol established in China and confirmation by physicians in Thailand show that a combination of Lopanvir and Ritonavir has worked on patients.
Top cancer drugs may come under price control
Taking cue from the WHO’s revised list of essential medicines, popular biosimilars for cancer c...
Treatments that can wait make private hospitals wait for revenue
The impact on revenue for private hospitals is expected to last for the next...
With OPDs & OTs shut, cancer, HIV & other patients struggle to get treatment
With the country's entire healthcare set-up working towards fighting Covid-19, patients of diseases like HIV, cancer and renal disease who need to access hospitals regularly to continue their treatment, and are immuno-compromised, are facing quite a bit of hardship with most OPDs and operation theatres closed.
Illegal cancer drugs from Bangladesh flood local market
Illegal import of drugs from Bangladesh and other neighbouring countries have further added to the woes of pharmaceutical companies. Experts suggest a thriving ‘grey’ market of fake and unapproved copies of Big Pharma’s oncology and hepatology medicines, and some under patent protection. The drugs are smuggled, hence exact numbers are unavailable.
US FDA accepts Biocon's cancer drug application for review
Biocon and Mylan’s proposed biosimilar bevacizumab, a cancer drug, is expected to be the third biosimilar from the partnered portfolio for patients in the US.
Biocon Biologics debuts in Asia IP Elite list
Biocon, the Bengaluru-headquartered bio-pharma firm and the parent company for Biocon Biologics, has has been recognised as the ASIA IP ELITE for the fourth year in a row. Biocon’s subsidiary received this award at the recently concluded IP Business Congress Asia in Tokyo, Japan. Biocon Biologics has a product pipeline of 28 molecules.
Prices of cancer, cardiac drugs may be slashed
This is a departure from the existing mechanism in which all essential medicines automatically go under price control. The Standing National Committee will decide which medicines should be available in adequate numbers and assured quality.
Lupin signs second partnership for its oncology pipeline, this time with German drug maker BI
BI and Lupin will together develop and commercialise a new drug called MEK inhibitor that will target specific cancer cells and potentially treat patients of skin and stomach cancer.
World Cancer Day: Have you been experiencing pain or swelling in bones for weeks? Time to visit the doctor
Bone cancer treatment includes combination chemotherapy and surgery.
Dr Reddy's launches Roche's Avastin biosimilar in India
The launch of Versavo is another step in that journey and helps in strengthening the company's oncology portfolio.
Sun Pharma eyes China, Japan markets
Shanghai now plans to steer the company into the specialty business (novel, innovative drugs), and towards expanding markets like China and Japan for growth, both through acquisitions and partnerships.
Price erosion symptoms: Dr Reddy's Laboratories plans to launch value-added drugs in US
Dr Reddy's Laboratories has said the company plans to launch several value-added products this fiscal tooffset the persisting problem.
Smallcap Hunters: Why Medicamen looks like a big story in the making
The company has built world-class facilities in terms of processes etc. No short cuts here.
70 products in pipeline,Dr Reddy's bullish on China
A top Commerce Department official recently said India pressed China to import more Indian goods, especially pharmaceutical and IT products.
Copyright © 2020 Bennett, Coleman & Co. Ltd. All rights reserved. For reprint rights: Times Syndication Service